CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors

Clinical trial for the safety and efficacy of CD19 CAR-T following autologous hematopoietic stem cell transplantation (ASCT) for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) with High-Risk Prognostic Factors

Trial Details

NCT ID
NCT06365671
Phase
PHASE2
Sponsor
Ruijin Hospital
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • autologous stem-cell transplantation
  • Relmacabtagene autoleucel (relma-cel)
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Histologically confirmed B-cell non-Hodgkin's lymphoma including the following types
  • diffuse large B-cell lymphoma
  • high-grade B-cell lymphoma with or without MYC and BLC2 and/or BCL6 rearrangement
  • transformed lymphoma

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →